This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rose, D. P. Articles by Davis, T. E. Search for Related Content PubMed PubMed Citation Articles by Rose, D. P. Articles by Davis, T. E.

Effects of Adjuvant Chemohormonal Therapy on the Ovarian and Adrenal Function of Breast Cancer Patients¹

Division of Clinical Oncology, Wisconsin Clinical Cancer Center, University of Wisconsin, Madison, Wisconsin 53792

Ovarian and adrenal function were studied in premenopausal breast cancer patients before and at intervals during adjuvant therapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF plus prednisone (CMFP), or CMFP plus tamoxifen (CMFPT). Amenorrhea developed within 10 months of starting therapy in 13 of 15 patients given CMF, 8 of 10 receiving CMFP, and all of 13 CMFPT-treated patients. The amenorrheic patients receiving CMF showed a reduction in their plasma total estrogens and an increase in plasma luteinizing and follicle-stimulating hormones, indicating that these cytotoxic drugs directly suppressed ovarian function. Plasma androstenedione levels, which are derived equally from the ovaries and adrenals before the menopause, were also reduced. Plasma dehydroepiandrosterone sulfate, a steroid predominantly of adrenal origin, was unaffected. CMFP-induced amenorrhea was associated with similar changes in the plasma estrogens and gonadotropins, but patients receiving this combination showed significantly greater reductions in plasma androstenedione and also decreased levels of plasma dehydroepiandrosterone sulfate. Suppression of androstenedione secretion from both the ovaries and adrenals did not affect the total plasma estrogen concentrations. Initially, CMFPT-treated patients showed significant elevations in plasma total estrogens, without a change in the gonadotropin levels. Although the plasma sex hormone-binding capacity was increased during CMFPT therapy, there was only a small reduction in the percentage of free plasma estradiol, with the result that the level of circulating unbound estrogen was increased. The plasma estrogens declined, with a corresponding increase in gonadotropins, after the onset of CMFPT-induced amenorrhea.

¹ Supported by Grants CA 14520 and CA 20432 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Human Oncology, Division of Clinical Oncology, Wisconsin Clinical Cancer Center, University of Wisconsin, 600 Highland Ave., Madison, Wis. 53792.

Received 5/ 2/80. Accepted 7/29/80.

This article has been cited by other articles:

				N. Denduluri, J. M. Walshe, and S. M. Swain In Reply J. Clin. Oncol., August 20, 2007; 25(24): 3788 - 3789. [Full Text] [PDF]

				J. M. Walshe, N. Denduluri, and S. M. Swain Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer J. Clin. Oncol., December 20, 2006; 24(36): 5769 - 5779. [Abstract] [Full Text] [PDF]

				M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, P. Veronesi, R. D. Gelber, G. Curigliano, R. Torrisi, A. Luini, et al. Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment Clin. Cancer Res., October 1, 2004; 10(19): 6622 - 6628. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, G. Martinelli, R. Gelber, A. Coates, and A. Goldhirsch Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean) Ann. Onc., February 1, 2004; 15(2): 355 - 356. [Full Text] [PDF]

				Z. Blumenfeld, I. Avivi, M. Ritter, and J. M. Rowe Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women Reproductive Sciences, September 1, 1999; 6(5): 229 - 239. [Abstract] [PDF]